Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
They can be found in the “never had any issues with weight control/I’m always forgetting to eat/I ate a small bag of chips so I’m not hungry” crowd